EUVIMEDEUVIMED entdecken
Crossref

Inhibition of SIRT4 promotes bladder cancer progression and immune escape via attenuating CD8+ T cells function

Jiancheng Lv, Yu Zhang, Qikai Wu, Peng Jiang, Yiwei Lin

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2024.113906 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Jiancheng Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Sirtuins, CD8-Positive T-Lymphocytes, Tumor Escape. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bladder cancer (BCa) is one of the most common malignancies of the urinary system and is characterized by a high recurrence rate and significant mortality. Sirtuin 4 (SIRT4), a member of the NAD+-dependent deacetylase and ADP-ribosyltransferase family, is involved in regulating cellular metabolism, DNA repair, and longevity, potentially influencing tumor progression and immune escape. This study aimed to elucidate the role of SIRT4 in BCa. METHODS: The correlation between the sirtuin family and immunotherapy sensitivity in BCa patients was analyzed via IMvigor210 data. The clinical significance and immunological role of SIRT4 across multiple cancer types were assessed by evaluating its associations with clinicopathologic features, prognosis, tumor mutation burden (TMB), microsatellite instability (MSI), immune cell infiltration, and immune response genes across 33 datasets from The Cancer Genome Atlas (TCGA). SIRT4 expression was confirmed in BCa tissues, and its functions were examined via proliferation and migration assays. CD8+ T cells were isolated from the peripheral blood of healthy individuals and activated with CD3 and CD28 antibodies and recombinant IL2. Coculture assays involving BCa cells and activated CD8+ T cells, alongside ELISA, were conducted to evaluate the immunological function of SIRT4. RESULTS: SIRT4 was positively associated with the immunotherapy response of BCa patients on the basis of IMvigor210 data. Its expression was downregulated in 11 tumor types but upregulated in 3. SIRT4 was significantly correlated with tumor stage in 2 tumor types and showed varying associations with overall survival, progression-free survival, and disease-specific survival. Additionally, SIRT4 was correlated with TMB in 10 tumor types and with MSI in 8. GSEA indicated that SIRT4 was negatively associated with the immune response in 9 tumor types, excluding BCa. It was positively correlated with immune cell infiltration in 2 tumor types and negatively correlated in 6. The TCGA data revealed that SIRT4 was positively associated with activated NK cell infiltration but negatively associated with M1 macrophages, neutrophils, resting NK cells, and activated memory CD4 T cells. Enrichment analyses revealed positive correlations with various chemokines, immunoinhibitors, immunostimulators, lymphocytes, MHC molecules, and MHC receptors, suggesting that SIRT4 may enhance the immune response in BCa. Further experiments confirmed that SIRT4 was downregulated in BCa tissues compared with adjacent normal tissues. Inhibition of SIRT4 promoted BCa cell proliferation and migration, whereas knockdown of SIRT4 impaired the chemotaxis and tumor-killing ability of CD8+ T cells in the BCa tumor microenvironment. CONCLUSIONS: In summary, SIRT4 inhibits the progression and immune escape of BCa, indicating its potential as a novel biomarker and immune checkpoint for immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsSirtuinsCD8-Positive T-LymphocytesTumor EscapeHumansFemaleMaleDisease ProgressionCell Line, TumorMiddle AgedCell ProliferationCell MovementLymphocytes, Tumor-InfiltratingAgedMitochondrial Proteins

Stichwörter der Autor:innen

BCaCD8(+) T cellsImmune escapePan-cancerProgressionSIRT4

Substanzen

SirtuinsSIRT4 protein, humanMitochondrial Proteins

Autor:innen und Institutionen

  • Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Urology, Xiangshan Hospital of Wenzhou Medical University, Ningbo, Zhejiang, China.
  • Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: 1507116@zju.edu.cn.
  • Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: zjulyw@zju.edu.cn.

Zitieren

APA

Lv, J., Zhang, Y., Wu, Q., Jiang, P., & Lin, Y. (2025). Inhibition of SIRT4 promotes bladder cancer progression and immune escape via attenuating CD8+ T cells function. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113906

Vancouver

Lv J, Zhang Y, Wu Q, Jiang P, Lin Y. Inhibition of SIRT4 promotes bladder cancer progression and immune escape via attenuating CD8+ T cells function. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113906

BibTeX
@article{Lv2025,
  author = {Lv, Jiancheng and Zhang, Yu and Wu, Qikai and Jiang, Peng and Lin, Yiwei},
  title = {Inhibition of SIRT4 promotes bladder cancer progression and immune escape via attenuating CD8+ T cells function},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2024.113906}
}
Kostenlos starten →